Cardiovascular risk profile in patients with myelopathy associated with HTLV-1

HAM/TSP (HTLV-1-associated myelopathy/tropical spastic paraparesis) is a slowly progressive disease, characterized by a chronic spastic paraparesis. It is not known if the disease carries an independent risk for cardiovascular disease. The objective of this study was to evaluate the cardiovascular r...

Full description

Saved in:
Bibliographic Details
Published in:The Brazilian journal of infectious diseases 2017-05, Vol.21 (3), p.226-233
Main Authors: Prado, Fabio Luís Silva do, Prado, Renata, Ladeia, Ana Marice Teixeira
Format: Article
Language:English
Subjects:
C reactive protein
Cardiac patients
Cardiovascular diseases
Cardiovascular Diseases - virology
Cardiovascular risk
Care and treatment
Cohort Studies
Comparative analysis
Cross-Sectional Studies
Diseases
Female
HAM/TSP
HTLV-1
Humans
INFECTIOUS DISEASES
Interleukin-6
Male
Medical research
Middle Aged
Original
Paraparesis, Tropical Spastic - complications
Risk Assessment
Risk Factors
Socioeconomic Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:HAM/TSP (HTLV-1-associated myelopathy/tropical spastic paraparesis) is a slowly progressive disease, characterized by a chronic spastic paraparesis. It is not known if the disease carries an independent risk for cardiovascular disease. The objective of this study was to evaluate the cardiovascular risk profile related to HAM/TSP and compare it with the general population. This was a cross-sectional study, with a control group. HAM/TSP patients were evaluated using cardiovascular risk scores (ASCVD RISK, SCORE and Framingham) and inflammatory markers (ultrasensitive CRP and IL-6), and compared with a control group of healthy individuals. We also evaluated the correlation between cardiovascular risk and the functional status of patients with HAM/TSP evaluated by the FIM scale. Eighty percent of patients in this study were females, mean age of 51 years (11.3). The control group showed an increased cardiovascular event risk in 10 years when ASCVD was analyzed (cardiovascular risk ≥7.5% in 10 years seen in 43% of patients in the control group vs. 23% of patients with HAM/TSP; p=0.037). There was no difference in ultrasensitive CRP or IL-6 values between the groups, even when groups were stratified into low and high risk. There was no correlation between the functional status of HAM/TSP patients and the cardiovascular risk. In this study, the cardiovascular risk profile of patients with HAM/TSP was better than the risk of the control group.
ISSN:1413-8670
1678-4391
1678-4391
DOI:10.1016/j.bjid.2017.01.007